Acute Decompensated Heart Failure: Evaluation and Management
Micro-brief created with inScope · Clinically reviewed by Yasmine Abbey, MD, MSc · Last reviewed:
Educational summary for clinicians. Not medical advice — verify against primary sources, your clinical judgment, and institutional protocols.
Bottom line
The cornerstone of acute decompensated heart failure is IV loop diuresis: start furosemide at a total daily IV dose equal to 1–2 times the prior oral dose (e.g., 40–80 mg IV every 6–12 hours for someone on 40 mg PO daily), then reassess urine output, weight, symptoms, and electrolytes within 2–4 hours and titrate — or switch to a continuous infusion — if the response is suboptimal.
Once the patient is euvolemic and blood pressure tolerates it, begin or up-titrate quadruple guideline-directed medical therapy for HFrEF before discharge: an ARNi (preferred over ACEi/ARB), an evidence-based beta-blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor.
Initial workup
- Baseline labs: CBC, BMP with BUN/creatinine, magnesium, phosphate, hepatic panel, troponin, and BNP/NT-proBNP to grade severity and identify precipitants.
- 12-lead ECG and chest X-ray to look for ischemia, arrhythmia, pulmonary congestion, or a precipitating cause.
- Transthoracic echocardiogram (if not recently done) to document ejection fraction and valve function for phenotype-directed therapy.
- Daily weights, strict intake/output, and a focused volume-status exam to trend the response to therapy.
Acute management
- IV loop diuretic: start furosemide at a total daily IV dose equal to 1–2 times the prior oral dose (e.g., 40–80 mg IV every 6–12 hours if on 40 mg PO daily); for diuretic-naive patients a 20–40 mg IV bolus is commonly used.
- Reassess urine output, weight, symptoms, and electrolytes within 2–4 hours; titrate the dose or consider a continuous infusion if the response is suboptimal.
- Sodium restriction (< 2 g/day) and, if hyponatremic or severely congested, fluid restriction (roughly 1.5–2 L/day).
- Supplemental oxygen only if SaO2 is < 90%.
- Continue or restart the chronic beta-blocker at the same or a lower dose if there is no cardiogenic shock or need for IV inotropes; hold it for symptomatic hypotension or bradycardia.
Inpatient and longitudinal management
- Begin or up-titrate quadruple GDMT for HFrEF before discharge once euvolemic and blood pressure tolerates: an ARNi (preferred over ACEi/ARB), an evidence-based beta-blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor.
- Allow a 36-hour washout when switching an ACE inhibitor to sacubitril/valsartan to reduce angioedema risk.
- Review vaccinations, provide low-sodium diet education, and teach daily weights and diuretic self-titration.
- Arrange early post-discharge follow-up (within 7 days) and home health or telemonitoring for high-risk patients.
Monitoring and disposition
- Daily weights, vital signs, and fluid balance; BMP and magnesium every 24 hours (or every 12 hours with high-dose diuresis).
- Goal: net negative 1–2 L/day, resolution of orthopnea and edema, and stable renal function and electrolytes.
- Transition to an oral diuretic regimen for ≥ 24 hours before discharge and document the target dry weight.
- Discharge once euvolemic, on optimized oral medications, and with a confirmed outpatient follow-up plan.
Escalate care if
- Urine output is < 100 mL/h or weight loss is < 0.5 kg/day after 24 hours — double the IV loop dose or change to a continuous infusion, and consider adding a thiazide-type diuretic (metolazone) after checking electrolytes.
- Progressive renal dysfunction, refractory congestion, or symptomatic hypotension develops — move to a higher level of care and consider ultrafiltration or IV vasodilators/inotropes per guideline.
- Arrhythmia, acute coronary syndrome, or cardiogenic shock occurs — activate the ICU/cardiology team and follow the shock pathway.
Duration
Continue IV diuresis until clinical euvolemia (often 2–5 days), then convert to oral diuretic maintenance.
Caveats
- Quadruple GDMT applies to HFrEF; tailor therapy to the heart-failure phenotype documented on echocardiography.
- Hold the beta-blocker or RAAS/ARNi therapy for symptomatic hypotension, bradycardia, or acute kidney injury with severe hyperkalemia.
References
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. (2022) · Primary guideline
- Meeting-in-a-Box: Heart Failure GDMT. · Primary guideline“Due to the risk of angioedema, ACE inhibitors should be held for 36 hours prior to initiation of sacubitril/valsartan.”
- Inpatient Initiation of HFrEF Therapies. · Primary guideline“Given the superior morbidity and mortality reduction with the ARNi sacubitril-valsartan, new practice guidelines recommend preferential treatment with ARNi whenever possible.”
- Appropriateness of diuretic dosing for patients with acute decompensated heart failure. Heart. · Systematic review“The European Society of Cardiology (ESC) guidelines for heart failure recommend starting IV furosemide at a daily dose equivalent to 1-2 times the daily oral dose pre-admission.”
- Diuretic Strategies in Patients with Acute Decompensated Heart Failure (DOSE). N Engl J Med. · Systematic review“Intravenous loop diuretics are an essential component of current treatment and are administered to approximately 90% of patients who are hospitalized with heart failure.”